Reviewing TG Therapeutics (TGTX) & The Competition

TG Therapeutics (NASDAQ:TGTX) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare TG Therapeutics to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Profitability

This table compares TG Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	11.81%	18.82%	7.78%
TG Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Analyst Ratings

This is a breakdown of current ratings for TG Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1	1	6	1	2.78
TG Therapeutics Competitors	9873	15286	45615	1598	2.54

TG Therapeutics presently has a consensus target price of $63.00, suggesting a potential downside of 2.42%. As a group, “Biotechnology” companies have a potential upside of 125.79%. Given TG Therapeutics’ peers higher possible upside, analysts clearly believe TG Therapeutics has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares TG Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TG Therapeutics	$616.29 million	$447.18 million	97.82
TG Therapeutics Competitors	$702.23 million	$9.48 million	-18.96

TG Therapeutics’ peers have higher revenue, but lower earnings than TG Therapeutics. TG Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

TG Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, TG Therapeutics’ peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Institutional & Insider Ownership

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

TG Therapeutics beats its peers on 10 of the 13 factors compared.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.